Kangethe James M, Monroe-Wise Aliza, Muiruri Peter N, Komu James G, Mutai Kenneth K, Nzivo Mirriam M, Pintye Jillian
Comprehensive Care Center, HIV Medicine, Kenyatta National Hospital, Nairobi, Kenya.
Department of Medical Microbiology and Immunology, Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya.
South Afr J HIV Med. 2022 Apr 25;23(1):1353. doi: 10.4102/sajhivmed.v23i1.1353. eCollection 2022.
In 2009, Kenyatta National Hospital (KNH) integrated cervical cancer screening within HIV care using visual inspection with acetic acid (VIA) and Pap smear cytology.
We evaluated utilisation of cervical cancer screening and human papillomavirus (HPV) vaccination among women living with HIV (WLHIV) receiving HIV care at KNH.
From November 2019 to February 2020, WLHIV aged ≥ 14 years were invited to participate in a survey following receipt of routine HIV services. We assessed awareness of cervical cancer, uptake of cervical cancer screening, uptake of the HPV vaccine, and barriers to utilisation of these services. In a subset of survey participants, focus group discussions (FGDs) were also conducted to identify screening barriers.
Overall, 305 WLHIV participated in the survey. Median age was 36 years (interquartile range [IQR]: 28-43), 41% were married, and 38% completed secondary education. Most (90%) had HIV RNA < 1000 copies/mL. Awareness of cervical cancer was high (84%), although only 45% of WLHIV had screened for cervical cancer at the referral hospital and only 13% knew how to prevent high-risk HPV. No participants had received an HPV vaccination. Older age, higher education, and knowledge of the HPV vaccine were associated with higher likelihood of cervical cancer screening ( < 0.05). In FGDs, barriers to utilising the services included user fees, fear of the procedure impacting fertility, age and gender of the provider, and long waiting times.
Despite integration with HIV services, the utilisation of cervical cancer screening was low among WLHIV and implementation barriers contributed to low utilisation.
2009年,肯雅塔国家医院(KNH)在艾滋病护理中采用醋酸肉眼观察法(VIA)和巴氏涂片细胞学检查将宫颈癌筛查纳入其中。
我们评估了在KNH接受艾滋病护理的感染艾滋病毒女性(WLHIV)中宫颈癌筛查和人乳头瘤病毒(HPV)疫苗接种的利用情况。
2019年11月至2020年2月,邀请年龄≥14岁的WLHIV在接受常规艾滋病服务后参与一项调查。我们评估了对宫颈癌的知晓情况、宫颈癌筛查的接受情况、HPV疫苗的接种情况以及这些服务利用的障碍。在一部分调查参与者中,还开展了焦点小组讨论(FGD)以确定筛查障碍。
总体而言,305名WLHIV参与了调查。中位年龄为36岁(四分位间距[IQR]:28 - 43),41%已婚,38%完成了中等教育。大多数(90%)的艾滋病毒核糖核酸(HIV RNA)<1000拷贝/毫升。对宫颈癌的知晓率较高(84%),尽管只有45%的WLHIV在转诊医院进行过宫颈癌筛查,只有13%知道如何预防高危HPV。没有参与者接种过HPV疫苗。年龄较大、教育程度较高以及对HPV疫苗的了解与宫颈癌筛查的可能性较高相关(<0.05)。在焦点小组讨论中,利用这些服务的障碍包括使用费、担心该程序影响生育、提供者的年龄和性别以及等待时间过长。
尽管与艾滋病服务相结合,但WLHIV中宫颈癌筛查的利用率较低,实施障碍导致了低利用率。